Transcell Biologics is an innovative biotech company with continuous discovery and process development as it’s a central theme to deliver unique disruptive stem cell-based solutions to treat chronic and debilitating diseases that have otherwise no options available to manage. The passionate leadership team is committed to developing therapies to address important medical needs through adult stem cell technologies by collaborating with clinicians and patient communities. Among the company’s landmark innovations in the development of a novel proprietary process for maximizing the therapeutic stem cell yield that also maintains the native pluripotent properties and inherent functionality. The Company has evolved from solely an R&D-focused biotech entity diversifying based on the intended applications of stem cell technologies
S Dravida, PhD
Subhadra Dravida, PhD is the Chief Executive Officer (CEO) of Transcell Biologics, an innovative biotech company based out of Hyderabad, India. The organization has continuous discovery and process development as its central theme in delivering unique disruptive stem cell-based solutions towards treating chronic and debilitating diseases that have otherwise no options available to manage.
Dr. Dravida is an entrepreneurial technocrat of global standing having worked in the USA, Canada, and India in the domains of stem cell research/bio-banking and product development (University of North Carolina USA, Ottawa Health Research Institute Canada, Center for Cellular and Molecular Biology and Hyderabad Eye Research Foundation). She has a unique blend of skills in the wet lab, from product development to managing a business.
Dr. Dravida leads the team and collaborations responsible for discovering druggable formulations across therapeutic areas and human surrogate in vitro cell/tissue microphysiological platforms for testing safety, the efficacy of pharma and biopharmaceuticals. Her role requires converging and executing both laboratory and clinical research programs across touchpoints.
Dr. Dravida has rich experience in adult stem cell technologies, predictive platform development and screening, large-scale preparations of primary cells, tumorospheres, low throughput, and high throughput platform technologies, cancer progenitor cells, cryopreservation technology, big data, drug discovery, pre-discovery process, etc.
Leela Krishna G
Leela is the Chief Operating Officer (COO) at Transcell Biologics. He is responsible for the day-to-day operational and general management of the teams and departments. In his role, Leela has developed R&D derived standard operating procedures, streamlined client/vendor associations, established facilities related to biomedical installations and operations at Transcell.
Leela has been instrumental in obtaining operational accreditations, certifications relevant to the domain. Leela is recognized by the NABL as an Internal Auditor. He also actively participates on various advisory boards for diagnostics, technical training, and skilling of the workforce.
Leela received his medical microbiology degree from Bharathidasan University and brings in more than fifteen years of operational management experience from the medical domain to the Transcell group. He regularly practices spiritual meditation and engages in community service in his spare time.
The Company has entered into an academic collaboration With Dr Reddy’s Institute of Life Sciences, India in 2016 for developing novel druggable chemistry of macrocyclic compounds tested for neuroprotective and neurogenesis properties on the Company’s proprietary adult stem cell platform technology; Sri Sai Dental College for Surgery, Vikarabad for stem cell research in periodontal applications; Parents Project for Muscular Dystrophy, India to research on progenitor cell formulations, pleiotropic integrated treatment regime for Muscular Dystrophies.
